Increased level of soluble interleukin-2 receptor in sera of patients with Graves' disease

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Soluble interleukin-2 receptor was studied in 20 patients with Graves' disease before and after methimazole treatment. Soluble interleukin-2 receptor level was significantly increased in newly diagnosed Graves' disease compared to controls (667 ± 270 vs 205 ± 45 U/ml) (P <0.001). In untreated patients' sera the soluble interleukin-2 receptor levels were higher in patients with active ophthalmopathy than in those without eye symptoms. Soluble interleukin-2 receptor levels were normalized in remission induced by methimazole treatment in the majority of patients except those with infiltrative ophthalmopathy. Furthermore, a correlation was found at the hyperthyroid stage of the disease between soluble interleukin-2 receptor level and titre of anti-TSH-receptor antibodies. However, the association with other parameters including anti-eye muscle, anti-thyroid peroxidase, anti-thyroglobulin antibodies was not significant.

Original languageEnglish
Pages (from-to)311-314
Number of pages4
JournalBiomedicine and Pharmacotherapy
Volume45
Issue number7
DOIs
Publication statusPublished - 1991

Fingerprint

Interleukin-2 Receptors
Graves Disease
Methimazole
Serum
Graves Ophthalmopathy
Iodide Peroxidase
Hyperthyroidism
Muscles
Therapeutics

Keywords

  • Graves' disease
  • methimazole treatment
  • soluble interleukin-2 receptor

ASJC Scopus subject areas

  • Pharmacology

Cite this

Increased level of soluble interleukin-2 receptor in sera of patients with Graves' disease. / Balázs, C.

In: Biomedicine and Pharmacotherapy, Vol. 45, No. 7, 1991, p. 311-314.

Research output: Contribution to journalArticle

@article{757e10013b704c0da8e03628cb8a190d,
title = "Increased level of soluble interleukin-2 receptor in sera of patients with Graves' disease",
abstract = "Soluble interleukin-2 receptor was studied in 20 patients with Graves' disease before and after methimazole treatment. Soluble interleukin-2 receptor level was significantly increased in newly diagnosed Graves' disease compared to controls (667 ± 270 vs 205 ± 45 U/ml) (P <0.001). In untreated patients' sera the soluble interleukin-2 receptor levels were higher in patients with active ophthalmopathy than in those without eye symptoms. Soluble interleukin-2 receptor levels were normalized in remission induced by methimazole treatment in the majority of patients except those with infiltrative ophthalmopathy. Furthermore, a correlation was found at the hyperthyroid stage of the disease between soluble interleukin-2 receptor level and titre of anti-TSH-receptor antibodies. However, the association with other parameters including anti-eye muscle, anti-thyroid peroxidase, anti-thyroglobulin antibodies was not significant.",
keywords = "Graves' disease, methimazole treatment, soluble interleukin-2 receptor",
author = "C. Bal{\'a}zs",
year = "1991",
doi = "10.1016/0753-3322(91)90086-9",
language = "English",
volume = "45",
pages = "311--314",
journal = "Biomedicine and Pharmacotherapy",
issn = "0753-3322",
publisher = "Elsevier Masson",
number = "7",

}

TY - JOUR

T1 - Increased level of soluble interleukin-2 receptor in sera of patients with Graves' disease

AU - Balázs, C.

PY - 1991

Y1 - 1991

N2 - Soluble interleukin-2 receptor was studied in 20 patients with Graves' disease before and after methimazole treatment. Soluble interleukin-2 receptor level was significantly increased in newly diagnosed Graves' disease compared to controls (667 ± 270 vs 205 ± 45 U/ml) (P <0.001). In untreated patients' sera the soluble interleukin-2 receptor levels were higher in patients with active ophthalmopathy than in those without eye symptoms. Soluble interleukin-2 receptor levels were normalized in remission induced by methimazole treatment in the majority of patients except those with infiltrative ophthalmopathy. Furthermore, a correlation was found at the hyperthyroid stage of the disease between soluble interleukin-2 receptor level and titre of anti-TSH-receptor antibodies. However, the association with other parameters including anti-eye muscle, anti-thyroid peroxidase, anti-thyroglobulin antibodies was not significant.

AB - Soluble interleukin-2 receptor was studied in 20 patients with Graves' disease before and after methimazole treatment. Soluble interleukin-2 receptor level was significantly increased in newly diagnosed Graves' disease compared to controls (667 ± 270 vs 205 ± 45 U/ml) (P <0.001). In untreated patients' sera the soluble interleukin-2 receptor levels were higher in patients with active ophthalmopathy than in those without eye symptoms. Soluble interleukin-2 receptor levels were normalized in remission induced by methimazole treatment in the majority of patients except those with infiltrative ophthalmopathy. Furthermore, a correlation was found at the hyperthyroid stage of the disease between soluble interleukin-2 receptor level and titre of anti-TSH-receptor antibodies. However, the association with other parameters including anti-eye muscle, anti-thyroid peroxidase, anti-thyroglobulin antibodies was not significant.

KW - Graves' disease

KW - methimazole treatment

KW - soluble interleukin-2 receptor

UR - http://www.scopus.com/inward/record.url?scp=0025881053&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025881053&partnerID=8YFLogxK

U2 - 10.1016/0753-3322(91)90086-9

DO - 10.1016/0753-3322(91)90086-9

M3 - Article

VL - 45

SP - 311

EP - 314

JO - Biomedicine and Pharmacotherapy

JF - Biomedicine and Pharmacotherapy

SN - 0753-3322

IS - 7

ER -